ArticleCureus2025
Evaluating the Role of Neurogenic Locus Notch Homolog Protein 1 in Oral Cancer Progression and Therapeutic Opportunities.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimThe most common type of malignancy on a global scale is oral cancer, as its incidence level is high worldwide. The neurogenic locus notch homolog protein 1 (NOTCH1) plays a key role in cell maturation and the regulation of the immune system; however, its functions are still not fully understood. This research evaluated the expression of NOTCH1 across two types of oral cancer (oral squamous cell carcinoma {OSCC} versus mucoepidermoid carcinoma {MEC}) and healthy controls to observe its correlation with immune suppression and patterns of disease progression.
methodsThis case-control study was conducted over a seven-month period from March 2023 to September 2023. A total of 120 participants were enrolled and divided into three equal groups, i.e., 40/120 (33.34%) OSCC cases, 40/120 (33.33%) MEC cases, and 40/120 (33.33%) healthy controls. The RNA extraction was done using a protocol, and blood and tumor tissues were taken for the purpose, after which cDNA was produced. The analysis was performed using NOTCH1-specific primers by quantitative real-time PCR (RT-qPCR). SPSS version 20 (Armonk, NY: IBM Corp.) was used for the calculation of expression quantities by employing the 2
resultsThe expression levels of NOTCH1 mRNA were seen to be substantially different across groups, with a mean of 3.67±0.59, while MEC patients displayed lower overexpression at 2.48±0.53, and controls maintained baseline expression at 1.00±0.42. NOTCH1 in stage IV cancers was more upregulated (4.03±0.48) than in stage III (3.26±0.56; p<0.001).
conclusionThe research demonstrated that NOTCH1 showed significant upregulation in oral squamous cell carcinoma and was associated with both immune suppression and unfavorable clinical outcomes. The investigation indicated that NOTCH1 stood as an effective biomarker and therapeutic target for oral cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.